John Wolleben

Managing Director at JMP Securities

Jonathan Wolleben is a Managing Director at Citizens JMP (JMP Securities), specializing in equity research of early-stage and mid-cap healthcare and biotechnology companies. He covers firms including Madrigal Pharmaceuticals, Larimar Therapeutics, Pharvaris, Astria Therapeutics, Quince Therapeutics, Ocular Therapeutix, Crinetics Pharmaceuticals, and others. Wolleben’s performance metrics include a 4.4-star analyst rating on TipRanks, a historical success rate ranging from 45%–50%, and average returns exceeding +19% on several recommendations, with individual calls such as a +416% return for Madrigal Pharmaceuticals and a 104% profit on Ocular Therapeutix. His career at JMP Securities began in late 2016, progressing from Associate Biotech Analyst through Senior Associate, Vice President, Director, and Managing Director since February 2023; previously, he earned BS and MS degrees from Carnegie Mellon University focusing on biological sciences and biotechnology management. He is FINRA-registered and possesses key securities licenses required for equity research.